For vinclozolin, the model established by the Authority to assess acute and chronic risk [http://www.efsa.europa.eu/en/mrls/docs/calculationacutechronic_2.xls] shows that a high level of consumer protection is maintained. This Regulation should therefore provide for a transitional arrangement, in order to allow normal marketing, processing and consumption of products which have been lawfully produced before the application of this Regulation.
Recital 13, Commission Regulation (EU) No 1138/2013 of 8 November 2013 amending Annexes II, III and…
In forcesince 8 Nov 2013